Core Insights - Swiss pharmaceutical firm Roche announced positive results from a phase II clinical trial of CT-388, an investigational dual GLP-1/GIP receptor aimed at treating obesity [1] Company Summary - Roche is developing CT-388 as a potential treatment for obesity, indicating a strategic focus on addressing metabolic disorders [1] Industry Summary - The positive results from the clinical trial highlight the ongoing innovation in the pharmaceutical industry, particularly in the area of obesity treatment [1]